Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

David J. Kuter(Massachusetts General Hospital), James B. Bussel(NewYork–Presbyterian Hospital), Roger M. Lyons(Hematology Oncology Associates), Vinod Pullarkat(City of Hope), Terry Gernsheimer(Bloodworks Northwest), Francis M. Senecal(Northwest Medical Specialties), Louis M. Aledort(Mount Sinai Hospital), James N. George(University of Oklahoma Health Sciences Center), Craig M. Kessler(Georgetown University), Miguel Á. Sanz(Leitat Technological Center), Howard A. Liebman(Keck Hospital of USC), Frank T. Slovick(Hematology Oncology Associates), J. Th. M. de Wolf(University Medical Center Groningen), Emmanuelle Bourgeois(Hôpital Claude Huriez), Troy H. Guthrie(Baptist Cancer Center), Adrian C. Newland(Royal London Hospital), Jeffrey S. Wasser(Community Cancer Center), Solomon I. Hamburg(Tower Cancer Research Foundation), Carlos Grande(Research Institute Hospital 12 de Octubre), François Lefrère(Hôpital Necker-Enfants Malades), Alan Lichtin(Cleveland Clinic), Michael D. Tarantino(Bleeding & Clotting Disorders Institute), Howard R. Terebelo(Newland Medical Associates), Jean‐François Viallard(Hôpital Cardiologique du Haut-Lévêque), Francis J. Cuevas(Marshall University), Ronald S. Go(Gundersen Health System), David H. Henry(Illinois CancerCare), Robert L. Redner(UPMC Hillman Cancer Center), Lawrence Rice(Baylor College of Medicine), Martin R. Schipperus(Rijnland Ziekenhuis), Ding‐Ding Guo(Amgen (United States)), Janet L. Nichol(Amgen (United States))
The Lancet
February 1, 2008
Cited by 861

Abstract


Related Papers

No related papers found

Powered by citation graph analysis